期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PCF与FOLFOX4方案治疗进展期胃癌的疗效观察 被引量：3

原文传递
导出
摘要 目的探讨PCF方案与FOLFOX4方案治疗进展期胃癌(AGC)的疗效及安全性、生存情况方面的差异。方法 94例AGC患者根据不同化疗方案分为两组。PCF组50例,紫杉醇35～50mg/m2,静滴3h,第1、8、15天;5-氟尿嘧啶(5-Fu)750mg/m2,持续静滴,第1～5天;顺铂(DDP)20mg/m2,静滴2h,第1～5天。FOLFOX4组44例,草酸铂85mg/m2,静滴2h,第1天;亚叶酸钙200mg/m2,静滴2h,第1、2天;5-Fu400mg/m2,静注,第1、2天,5-Fu600mg/m2,持续静脉泵输注22h,第1、2天。每2周为1个周期,2个周期后评判近期疗效、安全性,持续随访远期疗效。结果 PCF组总有效率(ORR)48.0%,疾病控制率(DCR)82.0%,中位生存期(MST)10.8个月,1年生存率36.0%;FOLFOX4组ORR45.5%,DCR81.8%,MST9.9个月,1年生存率34.1%;两组近、远期疗效无明显差异(P>0.05)。Ⅲ～Ⅳ度毒副反应主要为中性粒细胞减少、恶心呕吐。脱发发生率PCF组明显高于FOLFOX4组,外周神经毒性FOLFOX4组明显高于PFC组(均P<0.05)。结论 PCF方案与FOLFOX4方案治疗AGC的疗效和生存情况相似,毒副反应均可耐受。
作者 郭锦艳 沈华 徐振宇
机构地区 浙江警官职业学院卫生所 南京医科大学第一附属医院肿瘤科
出处 《苏州大学学报（医学版）》 CAS 北大核心 2010年第3期597-598,638,共3页 Suzhou University Journal of Medical Science
关键词 紫杉醇 草酸铂 进展期胃癌 化疗
分类号 R735.2 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Im CK,Jeung HC, Rha SY,et al. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer [ J ]. Cancer Chemother Pharmaco1,2008,61 ( 2 ) :315 - 321.
  • 2钟海均,张沂平,马胜林,应杰儿,杨云山,董勇.紫杉醇联合顺铂及氟尿嘧啶治疗晚期胃癌[J].中国癌症杂志,2006,16(12):1052-1054. 被引量：13
  • 3Van Cutsem E, Moiseyenko VM,Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group [J]. J Clin Oncol,2006,24(31 ) :4991 -4997.
  • 4Lorenzen S, Hentrich M, Haberl C, et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial [J]. Ann Oncol, 2007,18(10) :1673 - 1679.
  • 5Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil ; docetaxel and cisplatin ; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma : a randomized phase II trial of the Swiss Group for Clinical Cancer Research [ J ]. J Clin Oncol, 2007,25(22) :3217 - 3223.
  • 6Yamaguchi K, Nakagawa S, Yahusaki H,et al. Combination chemotherapy with 5-fluorouracil, cisplatin and paclitaxel for pretreated patients with advanced gastric cancer [J ]. Anticancer Res, 2007,27 ( 5 B ) : 3535 - 3539.
  • 7Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group[J]. J Clin Oncol,2007,25(22) :3210 -3216.

二级参考文献8

  • 1Kubota T.Theoretical basis for low-dose DDP/5-FU therapy[J].Jpn J Cancer Chemother,1999,26(11):1536-1541.
  • 2Furue H,Taguchi T.A Late phase Ⅱ study of RP56976(docetaxel) in patients with advanced or recurrent gastric cancer(Abstr)[J].Ann Oncol,1998,Suppl 4 (9):233P.
  • 3Ajani JA,Fairweather J,Dumas P,et al.Phase Ⅱ study oftaxol in patients with advanced gastric carcinoma[J].Cancer J Sci Am,1998,4(4):269-276.
  • 4Lokich JJ,Sonneborn H,Anderson NR,et al.Combined paclitaxel,cisplatin,and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas[J].Cancer,1999,85(11):2347-2351.
  • 5Sasaki T,Maeda Y,Kobayashi T,et al.New combination therapies for gastrointestinal cancer[J].Gan To Kagaku Ryoho,2000,27(3):348-355.
  • 6Cassidy J,Tabernero J,Twelves C,et al.XELOX (capecitabine plus oxaliplatin):active first-line therapy for patients with metastatic colorectal cancer[J].J Clin Oncol,2004,22:2084-2091.
  • 7Perez EA,Irwin DH,Patel R,et al.Multicenter phase Ⅱ trial of weekly paclitaxel in women with metastatic breast cancer[J].J Clin Oncol,2001,19(22):4216-4223.
  • 8金懋林.胃癌内科化学治疗的新进展[J].医学临床研究,2003,20(10):735-738. 被引量：69

共引文献12

同被引文献24

  • 1孙晓,万里新,孙东,魏光敏,王启船.FOLFOX4方案治疗进展期胃癌临床40例分析[J].中国现代药物应用,2007,1(7):40-41. 被引量：1
  • 2陈军,严超,朱正纲,燕敏,陈克敏,诸琦,刘炳亚,尹浩然,林言箴.内镜超声检查和多层螺旋CT对胃癌术前T、N分期的比较研究[J].中国实用外科杂志,2005,25(5):278-281. 被引量：17
  • 3季加孚.胃癌外科的现状与发展趋势[J].中国普外基础与临床杂志,2006,13(1):1-3. 被引量：65
  • 4Songun I, Putter H, Kranenbarg EM, et al. Smgical treatment of gastric cancer :15 -year follow-up results of the randomised nationwide Dutch DID2 trial [J]. Lancet Oncel, 2010,11 (5):439-449.
  • 5Yu M, Zheng HC ,Takahashi H, et al. Comparison in pathological be- haviours&prognosis of gastric cancers from general hospitals between China&Japan [J]. Indian J Med Res ,2010,132:295-302.
  • 6Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours., revised RECIST guideline (version 1.1). Eur J Cancer,2009,45(2) :228-247.
  • 7Trotti A, Colevas AD, Setser A, et al. CTCAE V3.0 : develop- ment of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 2003,13 (3) 176-181.
  • 8张信强.DCF方案对36例胃癌术前新辅助化疗的临床观察.临床探讨,2010,48(3):140-141.
  • 9Coimbra FJ, Costa WL Jr, Montagnini AL, et al. The inter- action between N-category and N-ratio as a new tool to im- prove lymph node metastasis staging in gastric cancer: results of a single cancer center in Brazi. Eur J Surg Oncol, 2011, 37 (1): 47-54.
  • 10李瑜英.康艾注射液联合FOLFOX4方案治疗进展期胃癌疗效观察[J].新中医,2008,40(11):23-24. 被引量：7

引证文献3

二级引证文献15

苏州大学学报（医学版）
2010年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部